How to write single-dose and repeat-dose toxicity reports

What makes a single- or repeat-dose toxicity report useful?

A useful report connects actual treatment, animal disposition, observations, pathology and exposure to the study scientist’s conclusions. Explain treatment relationship, adversity and recovery separately, preserving uncertainty and deviations. Describe the study conducted; neither its CTD placement nor a clean table establishes that the development program is adequately supported.

Before you begin

Preparation of existing general-toxicity studies. Species, duration, dose selection and whether a study is needed require product-specific scientific assessment.

What you will prepare: A controlled toxicity report with traceable findings, adverse-effect reasoning and a consistent toxicokinetic contribution.

Identify the study before applying a reporting outline

The toxicology family includes general, genetic, carcinogenic, reproductive, local and special-purpose evidence. Within general toxicity, distinguish a single-dose study from repeated administration, including any separate observation or recovery period. Record what was conducted; a range-finding study is not automatically a definitive study because it has the same species and route.

FDA's hierarchy identifies species and administration route for these report locations, with duration also relevant to repeat-dose organization. These are descriptive placement attributes, not a formula for deciding which studies must be run. In particular, do not infer that a standalone acute-toxicity study is necessary merely because 4.2.3.1 exists. The nonclinical owner should resolve development needs against the current product-specific evidence strategy.

Build a treatment-to-observation record

Collect the protocol and amendments, article characterization, formulation analysis, animal disposition, actual dosing records, clinical observations, body weight and food data, clinical pathology, organ assessments, histopathology and toxicokinetic contribution as applicable to the study. Record which endpoints were not assessed. The final narrative should describe the conducted study, including deviations that affect interpretation.

For single-dose work, retain the timing of early signs, deaths or euthanasia, the observation window and available pathological evidence. For repeat-dose work, separate on-treatment findings from observations after treatment stopped. Identify unscheduled removals and explain which analyses include those animals. A count discrepancy between disposition and result tables should be investigated before a conclusion is written.

Distinguish an observation from an adverse-effect conclusion

Present findings by dose, sex, time and relevant organ system, then explain the scientist's interpretation. Keep treatment relationship, adversity and reversibility as separate judgments with their supporting rationale. A statistically different value is not automatically adverse; absence of statistical significance does not by itself eliminate a biologically important observation.

If the report identifies a no-observed-adverse-effect level, reproduce the qualified study-specific conclusion and the evidence behind it. Do not assign a NOAEL mechanically to the highest dose with a nonsignificant comparison. A study may not establish the desired threshold; that is a finding to describe, not a formatting defect.

Connect toxicity observations to the appropriate exposure results using the correct analyte, sampling day, sex and dose. A nominal administered dose is not interchangeable with systemic exposure. Ask the toxicokinetic scientist to resolve differing metrics or incomplete measurements.

Review recovery and amendment claims critically

Fictional example: an organ finding is described as reversible because the group mean improved after treatment stopped. Individual records show persistent findings in some animals, and not all endpoints were measured during recovery. The reviewer should inspect the animal-level results and observation period, then qualify which changes improved and which remained unresolved.

If a pathology amendment changes a diagnosis, verify whether tables, the toxicological interpretation, any NOAEL statement and Module 2 summaries need revision. Preserve the amendment relationship and the actual approval process. An editorial rewrite must not overwrite a signed scientific conclusion without the responsible author's controlled correction.

Separate the decisions behind a toxicity conclusion

Use a finding record to stop a single reassuring label from concealing several scientific judgments. Populate it from the controlled study interpretation, not from a writer's independent reclassification.

Maintain an explicit “not established” outcome where the evidence does not support a decision. Do not turn a missing recovery measurement into “reversible,” or treat a statistical test as the entire adversity assessment.

Review exercise: a clinical chemistry change and a microscopic finding concern the same organ but occur in different animals or at different times. Before combining them into a causal explanation, ask the scientist to reconcile the underlying records. The final discussion may identify supporting concordance, a plausible relationship or remaining uncertainty. The table should preserve which conclusion was actually reached.

If the interpretation changes after a pathology amendment, trace its effect into the NOAEL discussion, exposure comparisons and toxicology summaries. Use the Module 4 release map to confirm the corrected versions travel together.

Frequently asked questions

Sources and revisions

Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.

Related guides